A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Phase 2/3Active, not recruiting
- Lead sponsor
- Bristol-Myers Squibb (Industry)
- Enrollment
- 470 (estimated)
- Start date
- 23 Oct 2025
- Primary completion
- 3 May 2029 (estimated)
- Study completion
- 3 May 2029
- Last update posted
- 3 Jun 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 6
Interventions
- Navlimetostat Drug
- Gemcitabine Drug
- Nab-paclitaxel Drug
- Placebo Drug
Conditions and primary outcome
- Pancreatic Ductal Adenocarcinoma
Primary outcome
Progression-Free Survival as assessed by Response Evaluation Criteria in Solid Tumors version v1.1 (RECIST v1.1) (Up to 3 years after last participant is randomized); Overall Survival (OS) (Up to 3 years after last participant is randomized)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07076121.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07076121 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.